Latest from Kromek

This latest order expansion is an endorsement of the strength of our detection solution and credentials as a high-quality product supplier.

The contract, which commences immediately, is worth at least $1.4 million and will be delivered over a three-year period.

Undertaken with new and existing institutional investors in the Company and was over-subscribed.

Kromek announces its interim results for the six months ended 31 October 2018. read and watch Arnab Basu (CEO) talk about the results.

Two new contracts for CZT based medical components: bone mineral densitometry and nuclear medicine.

An important milestone towards cash flow breakeven and pre-tax profits.